inFOCUS Gym for the Brain technology was developed in collaboration with scientists and engineers from top worldwide institutions. It is based on interdisciplinary approach combining neuroscience, neurotechnology, electrophysiology, neurogenetics, neuroimaging, neuropsychology and education. It is created with eco-friendly, recycled materials and developed through collaborative efforts among the world’s top laboratories.
Honeybee Robotics | ZP Engineering
Columbia University | New York University
Pitie-Salpetriere Hospital, Paris | La Sapienza University, Rome
Lana Morrow, Ph.D.
Founder and CEO
Dr. Morrow earned a doctoral degree in cognitive neuroscience from La Sapienza University in Rome, Italy, and went on to train at Mount Sinai Hospital in New York City at the invitation of professor Melvin Yahr. While working at the neurology department of Mount Sinai, she conducted studies using EEG-based brain mapping techniques with Parkinson’s patients. Afterwards she received further education and training in Clinical Neuropsychology under Dr. Yaakov Stern at Columbia Presbyterian Hospital in NYC.
As a Clinical Neuropsychologist, she has over 20 years of experience assessing and treating adults and children with various learning and neurological issues, specializing in the treatment of learning disabilities, attention deficit disorder and the differential diagnosis of complex brain disorders. As a neuroscientist, she used visual evoked potentials and other neuroimaging modalities to study brain functioning, completing successful research collaborations with major universities in Europe and the United States.
Most recently, Dr. Morrow created Focus Forum to provide patients with non-invasive, non-pharmacological methods for the diagnosis and remediation of patients with ADD/ADHD, Parkinson’s Disease, Alzheimer’s Disease, and age-related cognitive capacity, memory and focus deficits. Dr. Morrow’s vision is to help improve the quality of life for children and adults using simple, non-invasive systems. Collaborating with top scientists and engineers from leading universities around the world, Dr. Morrow conducts multidisciplinary clinical research and develops of hardware and software products for the purpose of delivering tangible benefits to millions around the globe.
Moses Chao, Ph.D.
White House Scientific Advisor
Professor of Molecular Neurobiology, NYU
President of Think Scientific Board
Past President of Society for Neuroscience
Moses V. Chao received his BA degree in biochemistry from Pomona College and his PhD from UCLA in 1980. He carried out postdoctoral research at Columbia University with Richard Axel, before joining the faculty at Cornell Medical School in 1984. In 1998, he moved to NYU School of Medicine, where he is presently Professor of Cell Biology, Physiology & Neuroscience and Psychiatry. His laboratory discovered and defined the genes encoding the NGF receptor. His research interests are to define the mechanisms used by trophic factors to change synaptic plasticity and prevent neurodegenerative diseases, such as Huntington’s and Alzheimer’s diseases. He has served as Senior Editor for the Journal of Neuroscience for eleven years and also as an editor for Developmental Neurobiology and Molecular and Cellular Neuroscience. He has also been a member of the Scientific Advisory Boards for the Simons Foundation, the Glaucoma Research Foundation, St. Jude’s Children’s Research Hospital. He has served as Chair of the Christopher and Dana Reeve Foundation, Board of Scientific Counselors for NICHD, the New York State Spinal Cord Research Injury Board and the European Brain Research Foundation. He was named a Fellow of the AAAS in 2007 and was a recipient of a Zenith Award from the Alzheimer’s Association; the Jacob Javits Neuroscience Investigator Award; and a Guggenheim Fellowship. In 2012, Chao was elected President of the Society for Neuroscience, which represents a nonprofit organization of 42,000 scientists and physicians who study the brain and nervous system.
Jaime Kulisevsky, MD
Dr Jaime Kulisevsky is Director of the Movement Disorders Unit at Sant Pau Hospital, Associate Professor at the Autonomous University of Barcelona and Coordinator of the postgraduate master degree in Neuropsychological Diagnosis and Rehabilitation. He has been engaged in neurological research for several years, has been recipient of several public research grants, and is currently Principal Investigator of Area II (Parkinson’s Disease) at the Biomedical Network Research Centre for Neurodegenerative Diseases (CIBERNED-Spain). He is an active member of the international Movement Disorder Society (MDS), where he presently pertains to the International Task Force for Developing Rating Scales for Parkinson’s disease, the Awards and the Web-Site committees. He acts as a reviewer on various scientific journals and is editor of the Movement Disorders section of the Journal ‘Frontiers in Neurology’ as well as being on the editorial board of Neurologia (the official journal of the Spanish Neurological Society) and Revista de Neurología. Dr Kulisevsky has published two sets of clinical guidelines on the treatment of Parkinson’s disease and more than 130 other papers in peer-reviewed journals, and he is a frequent speaker at national and international conferences and meetings. A particular research interest has been the cognitive and behavioural consequences of basal ganglia dysfunction and the impact of antiparkinsonian treatment on cognition in Parkinson’s disease. On 2008 was appointed Director of the Research Institute at the Hospital de la Santa Creu I Sant Pau (Universitat Autònoma de Barcelona).
Jean Christophe Corvol, MD, Ph.D.
Assistant Professor in Neuropharmacology
APHP, CRicm, UPMC, Inserm UMR_S975/CNRS UMR 7225, Pitié-Salpêtrière Hospital
ICM Institute for Brain and Spine, Paris
Jean-Christophe Corvol (JCC) is assistant professor in neuro-pharmacology at the Pitié-Salpêtrière Hospital. He has an MD in Neurology (2003), a PhD in neurosciences (2005) and he did a post-doc in the field of trancriptomic biomarkers (2006-2007, Molecular Neurogenetic Laboratory, UCSF, San Francisco). Since 2008, JCC heads the Neurosciences Clinical Research Center at the Pitié-Salpêtrière Hospital (APHP, INSERM, CIC-9503) and he is a principal investigator in the research team of Alexis Brice (CR-ICM).
JCC is a member of the French Society of Pharmacology, the French Society of Neurology, and the Movement Disorder Society. He is member of the scientific board of the European College of Neuropsychopharmacology, the French Association for Parkinson’s Disease, and the French Foundation for Brain Research.
His research is focused on drug development, biomarkers and pharmacogenetics of Parkinson’s disease. He has published more than 40 papers in international journals.